Outlook Therapeutics

$OTLK is a late clinical stage biopharma company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications.

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA™ (bevacizumab-vikg) as a Treatment for Wet AMD

https://t.co/4J0Kdnxi9S
$OTLK #RetinaDisease #Ophthalmology #wetAMD

[Outlook Therapeutics @OutlookTx]

Preserving vision remains at the core of our mission.

At Outlook Therapeutics, we are advancing innovative ophthalmic therapies with the goal of improving care for patients living with retinal diseases.

$OTLK #Ophthalmology #RetinaDisease #wetAMD

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

https://t.co/VDwNPMYvrh
$OTLK #RetinaDisease #Ophthalmology #wetAMD

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

https://t.co/WV1e9RVbIp
$OTLK

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

https://t.co/wCGC8DhyHa
$OTLK #RetinaDisease #Ophthalmology #wetAMD

[Outlook Therapeutics @OutlookTx]

Don’t miss what’s next from Outlook Therapeutics.
Get updates as they happen, from company news to key milestones, delivered straight to your inbox:

Subscribe here: https://t.co/kUs6vwGLL9

$OTLK #WetAMD #RetinalDisease

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

$OTLK https://t.co/Puwchggy9D
#RetinaDisease #Ophthalmology #wetAMD

[Outlook Therapeutics @OutlookTx]

Healthy Vision Month is a reminder to prioritize eye health and routine checkups.

At $OTLK, we are committed to enhancing the treatment of retinal disease.

#wetAMD #RetinalDisease

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

https://t.co/GxWkM0zMXP
$OTLK

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

https://t.co/VzusCABWNS
$OTLK

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

https://t.co/OFxvQLWyGL
$OTLK #RetinaDisease #Ophthalmology #wetAMD

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA

https://t.co/X2j4wwwI5C
$OTLK #RetinaDisease #Ophthalmology #wetAMD

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

https://t.co/c2JnAbX26X
$OTLK

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

https://t.co/jNNfuXTI0u
$OTLK

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces Proposed Public Offering

https://t.co/uik7nxfo6C
$OTLK

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

https://t.co/jN3LDONQBd
$OTLK #RetinaDisease #Ophthalmology #wetAMD

[Outlook Therapeutics @OutlookTx]

In recognition of #InternationalWomensDay, we would like to thank Dr. Julia Haller for her extraordinary contributions to #ophthalmology and for her service on the Board of Directors of $OTLK.

We congratulate her on her continued impact as CEO of Wills Eye Hospital!

[Outlook Therapeutics @OutlookTx]

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

https://t.co/pEMiCiw97f
$OTLK #RetinaDisease #Ophthalmology #wetAMD

[Outlook Therapeutics @OutlookTx]

Stay in the loop!

Be the first to know about our latest updates and announcements through our email alerts.
https://t.co/kUs6vwGLL9

$OTLK #WetAMD #RetinaDisease

[Outlook Therapeutics @OutlookTx]

We are pleased to welcome Dr. Felix Jede as Head of Germany and Austria, where he will play a key role in the sustainable expansion of our business, focusing on creating long-term value and establishing Outlook Therapeutics as a trusted partner within the ophthalmology community.